Today's Pre-Market Stock Movers: LI, BBBY, GSK, PTON and More

$Bed Bath & Beyond Inc (BBBY.US)$ +14.59% (Shares of Bed Bath & Beyond Inc. (BBBY) shot up 17.6% in premarket trading Monday toward a four-month high, putting the meme stock on track for a fourth-straight gain.)

$Plus Therapeutics (PSTV.US)$ +81.75% (Plus Therapeutics presented data from two ongoing trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for recurrent glioblastoma (GBM) and leptomeningeal metastases.)

$DouYu (DOYU.US)$ +10.40% (DouYu International Holdings Limited (NASDAQ:DOYU) reported a second-quarter FY22 revenue decline of 21.6% to $273.7 million year-on-year, beating the consensus of 263.99 million.)

American depository receipts of $Li Auto (LI.US)$ -6.3% after the Chinese electric-vehicle company guided for lower third-quarter deliveries than analysts expected. ADRs of fellow Chinese electric-vehicle makers also fell with $NIO Inc (NIO.US)$ down 1.8% and $XPeng (XPEV.US)$ declining 3.7%.

$Moderna (MRNA.US)$ bivalent Covid vaccine booster for adults aged 18 and older was authorized by a U.K. regulator. The stock fell 0.2%.

$Illinois Tool Works (ITW.US)$ was 2.2% lower after Deutsche Bank lowered its rating on the industrial products and equipment manufacturer to Sell from Hold.

$Peloton Interactive (PTON.US)$ was down 2.5% in premarket trading Monday after jumping 13.6% on Friday. The at-home fitness company said last week it was cutting nearly 800 jobs as part of a strategic overhaul.

$Walmart (WMT.US)$ , $Target (TGT.US)$ and $Home Depot (HD.US)$ will report second-quarter earnings results this week, with the reports giving investors some insight into how U.S. retail and the consumer are holding up amid a period of record-high inflation. All three stocks were little changed in the premarket session.

$GlaxoSmithKline (GSK.US)$ -4.55% (The market has priced in a potential legal settlement of more than $40 billion over allegedly carcinogenic effects of Zantac, a drug manufactured by various companies through the years, including GSK, Sanofi and Pfizer, Berenberg analysts say in a note. )